Sudhakar joined PPD in 2015 to serve as executive medical director of global product development in the Immunology/Rheumatology/Inflammation therapeutic area. The primary focus of his role is to strategically drive business across all the rheumatology/immunology franchise by utilizing his extensive global drug development and therapeutic medical expertise to create strategic plans for services utilizing a therapeutically focused consultative approach to clients in association with Phase I-IV programs.
Sudhakar a board-certified rheumatologist, comes to PPD from Pfizer where he served as a global clinical lead in the company’s global innovative pharma business division. This was after several years overseeing the progression of therapeutic candidates globally in the inflammation therapeutic area from IND through Phase II at Pfizer and Wyeth Pharmaceuticals.
Sudhakar has extensive knowledge of study design issues in the immunology area, trial endpoints, biomarker development, and the regulatory landscape, including participating at FDA meetings for defining key efficacy endpoints, and providing input into EMA regulatory guidance documents. He has developed highly productive relationships with KOLs and lupus organizations, has extensive experience in licensing assessments, due diligence, presentations to governance bodies and funding sources, and translational medicine experience including precision medicine strategies in inflammation.
Prior to joining the pharma industry, Sudhakar was on the staff and director of clinical research in the division of rheumatic and immunologic diseases at The Cleveland Clinic. He earned his medical degree from Chennai, India, and has a postgraduate degree in internal medicine from both Mumbai, India, and the UK. Sudhakar completed his residency in internal medicine from Abington Memorial Hospital, Pennsylvania, and his fellowship in rheumatology from The Cleveland Clinic.